Díaz J, Henao J, Rodelo J, García A, Arbeláez M, Jaimes F
Internal Medicine Department, San Vicente Foundation University Hospital, Medellín, Colombia; Department of Internal Medicine and Clinical Epidemiology Academic Group(GRAEPIC), University of Antioquia, Medellín, Colombia.
Renal Unit, San Vicente Foundation University Hospital, Medellín, Colombia; Department of Nephrology, University of Antioquia, Medellín, Colombia.
Transplant Proc. 2014 Jan-Feb;46(1):160-6. doi: 10.1016/j.transproceed.2013.07.070.
Incidence and risk factors for cytomegalovirus (CMV) disease in a Colombian cohort of kidney transplant recipients. CMV infection and disease are important causes of morbidity and mortality in kidney transplant recipients, and its prevalence varies with economic, geographic, and ethnic factors. Among 1620 records from a Colombian reference center, CMV immunoglobulin (Ig)G seroprevalence was found to be 90.9% among recipients and 90.2% among donors. In 86% (n = 264) of the cases, CMV disease occurred during the first 6 months after the transplantation, and the most frequent clinical presentation was CMV syndrome, followed by gastrointestinal disease. The following parameters were independent predictors of CMV disease: serological status of D+/R+ (hazard ratio [HR], 1.64; 95% confidence interval [CI], 1.03-2.63) and D+/R- (HR, 2.72; 95% CI, 1.49-4.93), age of the recipient (HR, 1.02; 95% CI, 1.01-1.03), and receiving more than 30 mg of prednisolone by the end of the first month after transplantation (HR, 1.59; 95% CI, 1.22-2.07). Acyclovir prophylaxis or other antiviral agents significantly decreased the risk of disease (HR, 0.41; 95% CI, 0.29-0.58 and HR, 0.34; 95% CI, 0.20-0.58, respectively). In conclusion, we found a high prevalence of CMV infection in a cohort of Latin American transplant recipients. In accord with findings from other regions, serological status is the main risk factor, prophylaxis with acyclovir is effective, and induction with alemtuzumab does not increase the risk of CMV disease.
哥伦比亚肾移植受者队列中巨细胞病毒(CMV)疾病的发病率及危险因素。CMV感染和疾病是肾移植受者发病和死亡的重要原因,其患病率因经济、地理和种族因素而异。在哥伦比亚一家参考中心的1620份记录中,发现受者中CMV免疫球蛋白(Ig)G血清阳性率为90.9%,供者中为90.2%。在86%(n = 264)的病例中,CMV疾病发生在移植后的前6个月,最常见的临床表现是CMV综合征,其次是胃肠道疾病。以下参数是CMV疾病的独立预测因素:D+/R+血清学状态(风险比[HR],1.64;95%置信区间[CI],1.03 - 2.63)和D+/R-(HR,2.72;95%CI,1.49 - 4.93)、受者年龄(HR,1.02;95%CI,1.01 - 1.03)以及移植后第一个月末接受超过30mg泼尼松龙(HR,1.59;95%CI,1.22 - 2.07)。阿昔洛韦预防或其他抗病毒药物显著降低了疾病风险(HR分别为0.41;95%CI,0.29 - 0.58和HR,0.34;95%CI,0.20 - 0.58)。总之,我们在一组拉丁美洲移植受者中发现CMV感染的患病率很高。与其他地区的研究结果一致,血清学状态是主要危险因素,阿昔洛韦预防有效,而用阿仑单抗诱导治疗不会增加CMV疾病的风险。